



# Drug Therapy Protocols: Furosemide

<b>Policy code</b>	DTP_FRU_0924
<b>Date</b>	September, 2024
<b>Purpose</b>	To ensure a consistent procedural approach to furosemide administration.
<b>Scope</b>	Applies to Queensland Ambulance Service (QAS) clinical staff.
<b>Health care setting</b>	Pre-hospital assessment and treatment.
<b>Population</b>	Applies to all ages unless stated otherwise.
<b>Source of funding</b>	Internal – 100%
<b>Author</b>	Clinical Quality & Patient Safety Unit, QAS
<b>Review date</b>	September, 2026
<b>Information security</b>	UNCLASSIFIED – Queensland Government Information Security Classification Framework.
<b>URL</b>	<a href="https://ambulance.qld.gov.au/clinical.html">https://ambulance.qld.gov.au/clinical.html</a>

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: [Clinical.Guidelines@ambulance.qld.gov.au](mailto:Clinical.Guidelines@ambulance.qld.gov.au)

## Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by appropriately qualified QAS clinicians when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

© State of Queensland (Queensland Ambulance Service) 2024.



This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>

For copyright permissions beyond the scope of this license please contact: [Clinical.Guidelines@ambulance.qld.gov.au](mailto:Clinical.Guidelines@ambulance.qld.gov.au)

# Furosemide

September, 2024

## Drug class

Loop diuretic<sup>[1,2]</sup>

## Pharmacology

Furosemide is a potent loop diuretic that acts by inhibiting sodium and chloride absorption in the ascending Loop of Henle (proximal and distal tubules).<sup>[1,2]</sup>

## Metabolism

The majority of parenteral furosemide is excreted in the urine within 24 hours, the remainder is excreted in the faeces.<sup>[1]</sup>

## Indications

- **Congestive cardiac failure**
- **Fluid overload** (with compromised renal function)
- **Oliguria** (after correction of hypotension and hypovolaemia)

## Contraindications

- Allergy AND/OR Adverse Drug Reaction
- Pre-hospital use in acute cardiogenic pulmonary oedema
- Patients less than 12 years of age

## Precautions

- Hypotension

## Side effects

- Marked diuresis can lead to hypotension
- Potassium loss associated with diuresis may aggravate or potentiate dysrhythmias

## Presentation

- Ampoule, 20 mg/2 mL *furosemide*

## Onset (IV)

3–5 minutes  
(peak 30 minutes)

## Duration (IV)

≈ 2 hours  
(following stat IV dose)

## Half-life

1.5 hours

**Schedule**

- S4 (Restricted drugs).

**Routes of administration**

Intravenous infusion (IV INF)



**Special notes**

- Ambulance officers must only administer medications for the listed indications and dosing range. Any consideration for treatment outside the listed scope of practice requires mandatory approval via the *QAS Clinical Consultation and Advice Line*.
- Increased infusion doses may be required in patients with chronic renal impairment and/or who take regular high dose oral furosemide.
- All cannulae and IV lines must be flushed thoroughly with sodium chloride 0.9% following each medication administration.

**Adult dosages**<sup>[1-3]</sup>

- **Congestive cardiac failure**
- **Fluid overload** (with compromised renal function)
- **Oliguria** (after correction of hypotension and hypovolaemia)



**IV  
INF**

CCP ESoP aeromedical – RSQ Clinical Coordinator consultation and approval required in all situations.

Continue furosemide infusions already commenced at hospital, using the same concentration and administration rate already established. This may involve withdrawing previously mixed and labelled solutions from the referring hospital. Should the RSQ Clinical Coordinator request a furosemide infusion be commenced, the following procedure must be undertaken.

Commence infusion at **5 mg/hour** (2.5 mL/hour) and increase by **5 mg/hour** (2.5 mL/hour) every **60 minutes** to a maximum dose of **20 mg/hour** (10 mL/hour) until the desired urine output is achieved.

***Syringe preparation:** Mix 100 mg (10 mL) of furosemide with 40 mL of sodium chloride 0.9% in a 50 mL syringe to achieve a final concentration of 2 mg/mL. Ensure all syringes are appropriately labelled. Administer via syringe driver.*

**Paediatric dosages**

**Note:** QAS officers are **NOT** authorised to administer furosemide to paediatric patients.